Scientific publications
Serum biomarkers for liver fibrosis assessment
Julia Maroto-García 1 , Ana Moreno-Álvarez 1 , María P Sanz de Pedro 2 , Antonio Buño-Soto 2 3 , Álvaro González 1 4
Abstract
Liver fibrosis is the result of chronic liver injury of different etiologies produced by an imbalance between the synthesis and degeneration of the extracellular matrix and dysregulation of physiological mechanisms.
Liver has a high regenerative capacity in the early stage of chronic diseases so a prompt liver fibrosis detection is important. Consequently, an easy and economic tool that could identify patients with liver fibrosis at the initial stages is needed.
To achieve this, many non-invasive serum direct, such as hyaluronic acid or metalloproteases, and indirect biomarkers have been proposed to evaluate liver fibrosis. Also, there have been developed formulas that combine these biomarkers, some of them also introduce clinical and/or demographic parameters, like FIB-4, non-alcoholic fatty liver disease fibrosis score (NFS), enhance liver fibrosis (ELF) or Hepamet fibrosis score (HFS).
In this manuscript we critically reviewed different serum biomarkers and formulas for their utility in the diagnosis and progression of liver fibrosis.
CITATION Adv Lab Med. 2024 Feb 14;5(2):131-147. doi: 10.1515/almed-2023-0172. eCollection 2024 Jun
Our authors
